Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Pneumococcal conjugate vaccine Stories

2013-07-03 12:24:04

DUBLIN, July 3, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/4bm2ld/pediatric) has announced the addition of the "Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis" [http://www.researchandmarkets.com/research/4bm2ld/pediatric ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Worldwide pediatric vaccine market has been growing rapidly over the last...

2013-06-06 12:29:16

DUBLIN, June 6, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/32gm2w/adult_and) has announced the addition of the "Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth" [http://www.researchandmarkets.com/research/32gm2w/adult_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Protection...

2013-05-22 12:30:46

PASADENA, Calif., May 22, 2013 /PRNewswire/ -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published today in Vaccine. The U.S. Food and Drug Administration approved PCV13 for use beginning in 2010 after a series of trials. These trials found that PCV13, which protects against a broader range of pneumococcal types than the...

2013-05-06 20:33:51

Technology will allow better surveillance of bacterial populations, understanding of vaccine effectiveness A new study led by researchers from Harvard School of Public Health (HSPH) and the Wellcome Trust Sanger Institute in the UK has, for the first time, used genome sequencing technology to track the changes in a bacterial population following the introduction of a vaccine. The study follows how the population of pneumococcal bacteria changed following the introduction of the 'Prevnar'...

2013-04-06 23:03:35

RnRMarketResearch.com adds latest market research report on “Adult and Adolescent Vaccines Market to 2018 — Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth” to its store. Dallas, TX (PRWEB) April 06, 2013 The report provides insights into the vaccines in the adult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depth analysis of the vaccines for the adult and adolescent...

2013-04-03 08:28:35

MALVERN, Pa., April 3, 2013 /PRNewswire/ -- Cathy Geddes, former commercial leader at Pfizer, Wyeth and Roche, has recently joined Delta Point, Inc. as Senior Vice President with responsibility for leading the operations of the business and developing innovative new marketing offerings. "Over the last few months Delta Point has brought in key talent who will enhance the company. In addition to Michael Hickey who recently joined as Senior Vice President of Global Leadership Development,...

2013-03-12 04:21:29

CAMBRIDGE, England, March 12, 2013 /PRNewswire/ -- ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately GBP0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax(TM), which targets a wide range of strains of the bacteria. This new grant follows the award of...

2013-01-04 12:23:11

ZURICH-SCHLIEREN, Switzerland, Jan. 4, 2013 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology. "Bacterial pathogens that exist in multiple pathogenic strains pose significant challenges for developing...

2012-12-21 16:23:02

WHITEHOUSE STATION, N.J., Dec. 21, 2012 /PRNewswire/ -- A gallon of gas cost 62 cents, the first Star Wars opened in movie theaters and disco ruled the dance floor. But 1977 was also a milestone year in science, technology and health care. In 1977: Apple Computer Inc. is incorporated The first MRI scan is performed on a human body The first pneumococcal polysaccharide vaccine is approved Science, technology and health care have evolved in many ways since 1977. For example, the...

2012-12-19 08:24:49

ZURICH-SCHLIEREN, Switzerland, Dec. 19, 2012 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced a collaboration with GlaxoSmithKline Biologicals (GSK) to develop new bacterial vaccines employing GlycoVaxyn's bio-conjugation technology. "GlycoVaxyn's technology is designed to enable or improve the development of anti-bacterial conjugate vaccines by in vivo synthesis of protein-polysaccharide complexes in E. coli, via recombinant DNA technology,"...